Authors


Christine Bestvina, MD

Latest:

Evaluating Ways to Maximize Immunotherapy Use in NSCLC

“We have huge amounts of work to do to maximize the efficacy of immunotherapy,” Christine Bestvina, MD, said during an interview with CancerNetwork.


Wayne G. Brisbane, MD

Latest:

AI May Assist in Prostate Cancer Diagnosis, Risk Stratification, and Treatment

Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.



Sridevi Rajeeve, MD

Latest:

CAR T in R/R MM: Key Takeaways and Pearls

Panelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.


Courtney Schepel, BS

Latest:

Integrative Oncology in Young Women With Breast Cancer

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.


Abigail Mateos-Soria, MD

Latest:

Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.



Doris Hansen, MD

Latest:

Best Practices for Referring Patients for CAR T Therapy

Panelists discuss the growing importance of early integration and collaboration between community oncologists and specialized centers in the evolving chimeric antigen receptor (CAR) T-cell therapy landscape for multiple myeloma, emphasizing timely referrals, coordinated care, and strategic sequencing with other immunotherapies to optimize patient outcomes.



Marytere Herrera-Martinez, MD

Latest:

Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?

A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.



Ira Winer, MD, PhD, FACOG

Latest:

Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer

Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.


Melissa Hardesty, MD, MPH

Latest:

Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer

Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.





Karthikeya Patil

Latest:

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.



Thinzar Min Lwin, MD, MS

Latest:

Molecular Diagnostics, PIPAC Appear "Exciting" in GI Cancer Surgical Care

Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.



Pouneh Razavi, MD

Latest:

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Jules Cohen, MD

Latest:

Evolving Landscape of HR+ Metastatic Breast Cancer Management

Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.



Viktor Grünwald, MD, PhD

Latest:

Future Directions in Advanced RCC

Panelists discuss future directions in the treatment of advanced renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.







Muddasir Hussain, MMBS, FCPS

Latest:

Squamous Cell Carcinoma of the Kidney: A Large Case Series

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.